{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:53:50Z","timestamp":1793148830377,"version":"4.5.0"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","award":["2024ZKZ005"],"award-info":[{"award-number":["2024ZKZ005"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014895","name":"Southwest Medical University","doi-asserted-by":"publisher","award":["2024SYF132"],"award-info":[{"award-number":["2024SYF132"]}],"id":[{"id":"10.13039\/501100014895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2022YFS0636"],"award-info":[{"award-number":["2022YFS0636"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115322","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:19:13Z","timestamp":1754407153000},"page":"115322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies"],"prefix":"10.1016","volume":"163","author":[{"given":"Zuolei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conggai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"16","key":"10.1016\/j.intimp.2025.115322_bb0010","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide [J]","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-023-01911-x","article-title":"Evolution of cell therapy for renal cell carcinoma [J]","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0020","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma [J]","volume":"16","author":"D\u00edAZ-MONTERO","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0025","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment Landscape of Renal Cell Carcinoma [J]","volume":"24","author":"Chen","year":"2023","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.intimp.2025.115322_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers [J]","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.intimp.2025.115322_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102881","article-title":"Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma [J]","volume":"133","author":"Santoni","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in Regulatory T Cells for Cancer Immunotherapy [J]","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ctrv.2015.07.002","article-title":"Metabolic alterations in renal cell carcinoma [J]","volume":"41","author":"Massari","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0050","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours [J]","volume":"82","author":"Moch","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2025.115322_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4797","article-title":"Renal cell carcinoma [J]","volume":"349","author":"Jonasch","year":"2014","journal-title":"Bmj"},{"key":"10.1016\/j.intimp.2025.115322_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103287","article-title":"Comprehensive review of chromophobe renal cell carcinoma [J]","volume":"160","author":"Garje","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0065","first-page":"8","article-title":"What\u2019s new in the WHO 2022 classification of kidney tumours? [J]","volume":"115","author":"Alaghehbandan","year":"2022","journal-title":"Pathologica"},{"issue":"14","key":"10.1016\/j.intimp.2025.115322_bb0070","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180080","article-title":"Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy [J]","volume":"134","author":"Zhou","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/imr.12812","article-title":"Future prospects for CD8(+) regulatory T cells in immune tolerance [J]","volume":"292","author":"Flippe","year":"2019","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0080","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer [J]","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0085","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects [J]","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115322_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T Cells and Human Disease [J]","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0095","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? [J]","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy [J]","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.intimp.2025.115322_bb0105","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1158\/0008-5472.CAN-20-2673","article-title":"Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFN\u03b3-Dependent Tumor Vessel Regression [J]","volume":"81","author":"Kurebayashi","year":"2021","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092314","article-title":"CXCR4\/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy [J]","volume":"14","author":"Mezzapelle","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.intimp.2025.115322_bb0115","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.trecan.2022.06.008","article-title":"Therapeutic targeting of regulatory T cells in cancer [J]","volume":"8","author":"Shan","year":"2022","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2011.10.035","article-title":"T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6 [J]","volume":"61","author":"Oldham","year":"2012","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0125","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3892\/mmr.2014.2778","article-title":"Skewed T-helper (Th)1\/2- and Th17\/T regulatory-cell balances in patients with renal cell carcinoma [J]","volume":"11","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0130","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1007\/s13277-014-3012-8","article-title":"Comparison of circulating and intratumoral regulatory T cells in patients with renal cell carcinoma [J]","volume":"36","author":"Asma","year":"2015","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.imbio.2011.07.032","article-title":"IL-12 inhibits the TGF-\u03b2-dependent T cell developmental programs and skews the TGF-\u03b2-induced differentiation into a Th1-like direction [J]","volume":"217","author":"Prochazkova","year":"2012","journal-title":"Immunobiology"},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24097946","article-title":"The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma [J]","volume":"24","author":"Monjaras-Avila","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0145","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.4049\/jimmunol.172.9.5149","article-title":"Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7 [J]","volume":"172","author":"Fantini","year":"2004","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115322_bb0150","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1600-6143.2004.00566.x","article-title":"TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors [J]","volume":"4","author":"Fu","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0155","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 [J]","volume":"198","author":"Chen","year":"2003","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/eji.201646716","article-title":"TGF-\u03b2 regulation of encephalitogenic and regulatory T cells in multiple sclerosis [J]","volume":"47","author":"Lee","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/imr.12199","article-title":"Complex interactions of transcription factors in mediating cytokine biology in T cells [J]","volume":"261","author":"Li","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.115322_bb0170","article-title":"Role of Cytokines in Thymic Regulatory T Cell Generation: Overview and Updates [J]","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2045-3701-1-20","article-title":"Role of dendritic cells in the induction of regulatory T cells [J]","volume":"1","author":"Kushwah","year":"2011","journal-title":"Cell Biosci"},{"issue":"8","key":"10.1016\/j.intimp.2025.115322_bb0180","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1084\/jem.20070602","article-title":"Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid [J]","volume":"204","author":"Sun","year":"2007","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0185","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers [J]","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115322_bb0190","doi-asserted-by":"crossref","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases [J]","volume":"14","author":"Hossen","year":"2023","journal-title":"Front. Immunol."},{"issue":"7851","key":"10.1016\/j.intimp.2025.115322_bb0195","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid [J]","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0200","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s00262-021-02881-z","article-title":"Metabolic profiles of regulatory T cells in the tumour microenvironment [J]","volume":"70","author":"Rao","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"13","key":"10.1016\/j.intimp.2025.115322_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137346","article-title":"Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression [J]","volume":"25","author":"Wang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0210","doi-asserted-by":"crossref","first-page":"2460281","DOI":"10.1080\/2162402X.2025.2460281","article-title":"Leptin decreases Th17\/Treg ratio to facilitate neuroblastoma via inhibiting long-chain fatty acid catabolism in tumor cells [J]","volume":"14","author":"Li","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2025.115322_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113952","article-title":"Unleashing the Power of immune Checkpoints: A new strategy for enhancing Treg cells depletion to boost antitumor immunity [J]","volume":"147","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115322_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114180","article-title":"Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis [J]","volume":"158","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/biom14121646","article-title":"Lactate and Lactylation: Dual Regulators of T-Cell-Mediated Tumor Immunity and Immunotherapy [J]","volume":"14","author":"Hao","year":"2024","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0230","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41467-020-17750-z","article-title":"Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine [J]","volume":"11","author":"Campesato","year":"2020","journal-title":"Nat. Commun."},{"issue":"6145","key":"10.1016\/j.intimp.2025.115322_bb0235","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis [J]","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.313","article-title":"Transcriptional regulation and development of regulatory T cells [J]","volume":"50","author":"Lee","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0245","doi-asserted-by":"crossref","first-page":"9533","DOI":"10.1038\/s41598-024-59746-5","article-title":"Low ACADM expression predicts poor prognosis and suppressive tumor microenvironment in clear cell renal cell carcinoma [J]","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mam.2011.11.001","article-title":"Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance [J]","volume":"33","author":"Cassani","year":"2012","journal-title":"Mol. Asp. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0255","doi-asserted-by":"crossref","first-page":"1166s","DOI":"10.3945\/ajcn.112.034637","article-title":"Vitamin A and retinoic acid in T cell-related immunity [J]","volume":"96","author":"Ross","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0260","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s12094-023-03080-1","article-title":"The prognostic values of FOXP3(+) tumor-infiltrating T cells in breast cancer: a systematic review and meta-analysis [J]","volume":"25","author":"Sun","year":"2023","journal-title":"Clin. Transl. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0265","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance [J]","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"7090","key":"10.1016\/j.intimp.2025.115322_bb0270","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J]","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells [J]","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0280","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy [J]","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103257","article-title":"Research advances on targeted-Treg therapies on immune-mediated kidney diseases [J]","volume":"22","author":"Li","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0290","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.4049\/jimmunol.1500801","article-title":"Control of Regulatory T Cell Migration, Function, and Homeostasis [J]","volume":"195","author":"Campbell","year":"2015","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0295","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cei\/uxac078","article-title":"Regulatory T-cell therapy approaches [J]","volume":"211","author":"Mccallion","year":"2023","journal-title":"Clin. Exp. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115322_bb0300","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.it.2013.08.003","article-title":"Transcriptional control of regulatory T cell development and function [J]","volume":"34","author":"Luo","year":"2013","journal-title":"Trends Immunol."},{"issue":"D1","key":"10.1016\/j.intimp.2025.115322_bb0305","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics [J]","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.intimp.2025.115322_bb0310","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/eji.202149358","article-title":"Regulatory T-cell development in the tumor microenvironment [J]","volume":"52","author":"Itahashi","year":"2022","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.11.004","article-title":"Regulatory T cells and TGF-\u03b21 in clinically localized renal cell carcinoma: Comparison with age-matched healthy controls [J]","volume":"33","author":"Kim","year":"2015","journal-title":"Urol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0320","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/imr.12170","article-title":"Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation [J]","volume":"259","author":"Smigiel","year":"2014","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0325","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1111\/cas.13996","article-title":"Immune infiltration in renal cell carcinoma [J]","volume":"110","author":"Zhang","year":"2019","journal-title":"Cancer Sci."},{"issue":"6127","key":"10.1016\/j.intimp.2025.115322_bb0330","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4 [J]","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.intimp.2025.115322_bb0335","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms [J]","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"issue":"28","key":"10.1016\/j.intimp.2025.115322_bb0340","doi-asserted-by":"crossref","first-page":"10398","DOI":"10.1073\/pnas.0403342101","article-title":"Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease [J]","volume":"101","author":"Paust","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0345","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy [J]","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"issue":"30","key":"10.1016\/j.intimp.2025.115322_bb0350","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells [J]","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.intimp.2025.115322_bb0355","article-title":"Function and Role of Regulatory T Cells in Rheumatoid Arthritis [J]","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115322_bb0360","article-title":"CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis [J]","volume":"11","author":"Soskic","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0365","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5570","article-title":"Anti-PD-1\/PD-L1 and anti-CTLA-4 associated checkpoint inhibitor pneumonitis in non-small cell lung cancer: Occurrence, pathogenesis and risk factors (Review) [J]","volume":"63","author":"Hu","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells [J]","volume":"96","author":"SASIDHARAN NAIR V, ELKORD E.","year":"2018","journal-title":"Immunol. Cell Biol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0375","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J]","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0380","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-024-02059-y","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives [J]","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0385","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function [J]","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.115322_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115142","article-title":"Why Treg should be the focus of cancer immunotherapy: The latest thought [J]","volume":"168","author":"Liu","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb0395","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.semcancer.2012.03.004","article-title":"What are regulatory T cells (Treg) regulating in cancer and why? [J]","volume":"22","author":"Whiteside","year":"2012","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0400","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion [J]","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.115322_bb0405","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/171520","article-title":"Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells [J]","volume":"2015","author":"Ronchetti","year":"2015","journal-title":"J Immunol Res"},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0410","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1002\/eji.200939684","article-title":"Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg [J]","volume":"39","author":"Stockis","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"32","key":"10.1016\/j.intimp.2025.115322_bb0415","doi-asserted-by":"crossref","first-page":"13445","DOI":"10.1073\/pnas.0901944106","article-title":"GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells [J]","volume":"106","author":"Tran","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0420","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tmrv.2016.07.003","article-title":"Regulatory T Cells: Central Concepts from Ontogeny to Therapy [J]","volume":"31","author":"Khor","year":"2017","journal-title":"Transfus. Med. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103085","article-title":"Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases [J]","volume":"21","author":"Gertel","year":"2022","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb0430","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.immuni.2004.09.002","article-title":"Human T regulatory cells can use the perforin pathway to cause autologous target cell death [J]","volume":"21","author":"Grossman","year":"2004","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0435","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.4049\/jimmunol.181.7.4752","article-title":"Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells [J]","volume":"181","author":"Gondek","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0440","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","article-title":"Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity [J]","volume":"15","author":"Yan","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0445","first-page":"2120","article-title":"Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma [J]","volume":"125","author":"Ning","year":"2012","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0450","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1038\/s41467-024-49282-1","article-title":"Immunological synapse formation between T regulatory cells and cancer-associated fibroblasts promotes tumour development [J]","volume":"15","author":"Varveri","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb0455","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/his.14700","article-title":"WHO 2022 landscape of papillary and chromophobe renal cell carcinoma [J]","volume":"81","author":"Lobo","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000217","article-title":"Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report [J]","volume":"8","author":"Zeng","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"9669","key":"10.1016\/j.intimp.2025.115322_bb0465","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma [J]","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0470","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s44276-025-00128-3","article-title":"A novel multigene panel (Sig27) robustly predicts poor prognosis of renal cell carcinoma via high-level associations with immunosuppressive features [J]","volume":"3","author":"Dong","year":"2025","journal-title":"BJC Rep"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0475","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/his.13987","article-title":"Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma [J]","volume":"76","author":"Eich","year":"2020","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0480","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cam4.1905","article-title":"Construction of immune-related risk signature for renal papillary cell carcinoma [J]","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2025.115322_bb0485","doi-asserted-by":"crossref","first-page":"1182581","DOI":"10.3389\/fimmu.2023.1182581","article-title":"Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles [J]","volume":"14","author":"Govindarajan","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115322_bb0490","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","article-title":"Chromophobe renal cell carcinoma [J]","volume":"41","author":"Henske","year":"2023","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.intimp.2025.115322_bb0495","first-page":"1","article-title":"Characterization of the immunophenotype and tumor specificity of CD8+T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms [J]","volume":"41","author":"Labaki","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0500","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1464-410X.2008.08151.x","article-title":"The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma [J]","volume":"103","author":"Li","year":"2009","journal-title":"BJU Int."},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0505","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s00262-004-0646-1","article-title":"Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas [J]","volume":"54","author":"C\u00f3zar","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.intimp.2025.115322_bb0510","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00262-007-0318-z","article-title":"Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival [J]","volume":"56","author":"Griffiths","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2025.115322_bb0515","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis [J]","volume":"5","author":"Shang","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0520","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/CJI.0b013e3181fb6580","article-title":"Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-\u03b21 mRNA expression in peripheral blood mononuclear cells [J]","volume":"34","author":"Busse","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2025.115322_bb0525","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.euros.2020.06.003","article-title":"Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma [J]","volume":"20","author":"Davidsson","year":"2020","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0530","article-title":"Number of FoxP3+ regulatory T-cells are associated with recurrence in vulvar squamous cell carcinoma [J]","volume":"34","author":"AR\u0131K D, BENLI T, TELLI E.","year":"2023","journal-title":"J. Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115322_bb0535","first-page":"5039","article-title":"CD8(+) cytotoxic and FoxP3(+) regulatory T lymphocytes serve as prognostic factors in breast cancer [J]","volume":"11","author":"Peng","year":"2019","journal-title":"Am. J. Transl. Res."},{"issue":"36","key":"10.1016\/j.intimp.2025.115322_bb0540","article-title":"SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T-Cells Infiltration and Immunosuppression [J]","volume":"11","author":"Luo","year":"2024","journal-title":"Adv Sci (Weinh)"},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0545","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1464-410X.2010.09555.x","article-title":"Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma [J]","volume":"107","author":"Liotta","year":"2011","journal-title":"BJU Int."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020227","article-title":"Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma [J]","volume":"11","author":"Seminerio","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0555","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","article-title":"Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer [J]","volume":"27","author":"Salama","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0560","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-022-02205-0","article-title":"Correlation and prognostic implications of intratumor and tumor draining lymph node Foxp3(+) T regulatory cells in colorectal cancer [J]","volume":"22","author":"Yan","year":"2022","journal-title":"BMC Gastroenterol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0565","first-page":"8227","article-title":"High intratumoral FOXP3+ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer [J]","volume":"8","author":"Hanke","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0570","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s41379-022-01086-8","article-title":"Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer [J]","volume":"35","author":"Bergsland","year":"2022","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0575","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3233\/BD-239002","article-title":"FOXP3 regulatory T cells on prognosis of breast cancer [J]","volume":"42","author":"Usman","year":"2023","journal-title":"Breast Dis"},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0580","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies [J]","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2025.115322_bb0585","first-page":"73","article-title":"Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities [J]","volume":"2","author":"Graves","year":"2013","journal-title":"Immunotargets Ther"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010034","article-title":"Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma [J]","volume":"13","author":"Meng","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0595","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.urolonc.2021.04.013","article-title":"Papillary renal cell carcinoma: Review [J]","volume":"39","author":"Mendhiratta","year":"2021","journal-title":"Urol. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb0600","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MOU.0000000000001000","article-title":"Papillary renal cell carcinoma: current and controversial issues [J]","volume":"32","author":"Angori","year":"2022","journal-title":"Curr. Opin. Urol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0605","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pathol.2020.09.015","article-title":"Chromophobe renal cell carcinoma: current and controversial issues [J]","volume":"53","author":"Moch","year":"2021","journal-title":"Pathology"},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0610","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.3390\/cimb45060303","article-title":"Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas [J]","volume":"45","author":"Hu","year":"2023","journal-title":"Curr Issues Mol Biol"},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0615","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1016\/j.asjsur.2023.03.148","article-title":"Renal collecting duct carcinoma: A case report and literature review [J]","volume":"46","author":"Deng","year":"2023","journal-title":"Asian J Surg"},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0620","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.urolonc.2021.04.041","article-title":"\u201cCollecting duct carcinoma of the kidney: diagnosis and implications for management\u201d [J]","volume":"40","author":"Cabanillas","year":"2022","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0625","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5114\/pjp.2018.76693","article-title":"A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects [J]","volume":"69","author":"Kuroda","year":"2018","journal-title":"Pol. J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0630","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.drudis.2021.07.009","article-title":"Renal cell carcinoma therapy: Current and new drug candidates [J]","volume":"27","author":"Pontes","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0635","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.165","article-title":"The significance of intertumor and intratumor heterogeneity in liver cancer [J]","volume":"50","author":"Liu","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2025.115322_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111746","article-title":"Identification of Treg-related prognostic molecular subtypes and individualized characteristics in clear cell renal cell carcinoma through single-cell transcriptomes and bulk RNA sequencing [J]","volume":"130","author":"Weng","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"20","key":"10.1016\/j.intimp.2025.115322_bb0645","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/1078-0432.CCR-10-1757","article-title":"Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I\/II study in metastatic melanoma patients [J]","volume":"16","author":"Jacobs","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0650","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/exd.14721","article-title":"Significance of regulatory T cells in cancer immunology and immunotherapy [J]","volume":"32","author":"Sugiyama","year":"2023","journal-title":"Exp. Dermatol."},{"issue":"44","key":"10.1016\/j.intimp.2025.115322_bb0655","doi-asserted-by":"crossref","first-page":"77110","DOI":"10.18632\/oncotarget.20363","article-title":"Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer [J]","volume":"8","author":"Santagata","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0660","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41416-024-02702-x","article-title":"Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients [J]","volume":"130","author":"Santagata","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0665","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1038\/s41467-021-26091-4","article-title":"CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells [J]","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy [J]","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0675","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments [J]","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0680","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/intimm\/dxad035","article-title":"Metabolic advantages of regulatory T cells dictated by cancer cells [J]","volume":"36","author":"Kondo","year":"2024","journal-title":"Int. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0685","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 [J]","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2025.115322_bb0690","doi-asserted-by":"crossref","first-page":"1195500","DOI":"10.3389\/fendo.2023.1195500","article-title":"Metabolic reprogramming of clear cell renal cell carcinoma [J]","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0695","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/08830185.2020.1836176","article-title":"Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases [J]","volume":"41","author":"Heidari","year":"2022","journal-title":"Int. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188559","article-title":"Metabolic reprogramming in renal cancer: Events of a metabolic disease [J]","volume":"1876","author":"Chakraborty","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0705","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","article-title":"Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets [J]","volume":"20","author":"Tan","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.intimp.2025.115322_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154302","article-title":"Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression [J]","volume":"110","author":"Noh","year":"2020","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb0715","first-page":"169","article-title":"Evaluation of the lipid composition of human healthy and neoplastic renal tissues [J]","volume":"53","author":"Tugnoli","year":"2004","journal-title":"Ital J Biochem"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0720","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2020.06.016","article-title":"An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells [J]","volume":"53","author":"Kumagai","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0725","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.celrep.2019.03.029","article-title":"HIF-1\u03b1 Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma [J]","volume":"27","author":"Miska","year":"2019","journal-title":"Cell Rep."},{"issue":"28","key":"10.1016\/j.intimp.2025.115322_bb0730","doi-asserted-by":"crossref","first-page":"E6546","DOI":"10.1073\/pnas.1720113115","article-title":"Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth [J]","volume":"115","author":"Pacella","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0735","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and Beyond in Cancer Immunotherapy [J]","volume":"38","author":"Wrangle","year":"2018","journal-title":"J. Interf. Cytokine Res."},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0740","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2217\/imt.14.78","article-title":"High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented? [J]","volume":"6","author":"Muhitch","year":"2014","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0745","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the Treatment of Cancer [J]","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.intimp.2025.115322_bb0750","doi-asserted-by":"crossref","first-page":"1325575","DOI":"10.3389\/fonc.2024.1325575","article-title":"Th17\/Treg cell balance in patients with papillary thyroid carcinoma: a new potential biomarker and therapeutic target [J]","volume":"14","author":"Huo","year":"2024","journal-title":"Front. Oncol."},{"issue":"6029","key":"10.1016\/j.intimp.2025.115322_bb0755","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 [J]","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0760","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells [J]","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0765","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma [J]","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb0770","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma [J]","volume":"18","author":"Braun","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0775","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.trecan.2024.10.009","article-title":"Advances in LAG3 cancer immunotherapeutics [J]","volume":"11","author":"Adam","year":"2025","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2025.115322_bb0780","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-025-02990-x","article-title":"First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors [J]","volume":"132","author":"Day","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0785","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J]","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0790","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13197","article-title":"The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy [J]","volume":"96","author":"Mohsenzadegan","year":"2022","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0795","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy [J]","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0800","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrc1926","article-title":"Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer [J]","volume":"6","author":"Bierie","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0805","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14728222.2017.1275568","article-title":"Garp as a therapeutic target for modulation of T regulatory cell function [J]","volume":"21","author":"Shevach","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"Pt 6","key":"10.1016\/j.intimp.2025.115322_bb0810","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/brain\/aww084","article-title":"MicroRNAs targeting TGF\u03b2 signalling underlie the regulatory T cell defect in multiple sclerosis [J]","volume":"139","author":"Severin","year":"2016","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0815","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.7150\/thno.51383","article-title":"Targeting transforming growth factor-\u03b2 signaling for enhanced cancer chemotherapy [J]","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0820","first-page":"507","article-title":"Treatment of renal cell carcinoma: Current status and future directions [J]","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0825","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2017.28.e64","article-title":"Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer [J]","volume":"28","author":"Zhu","year":"2017","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2025.115322_bb0830","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment [J]","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0835","doi-asserted-by":"crossref","DOI":"10.1002\/biof.2143","article-title":"Deciphering potential molecular mechanisms in clear cell renal cell carcinoma based on the ubiquitin-conjugating enzyme E2 related genes: Identifying UBE2C correlates to infiltration of regulatory T cells [J]","volume":"51","author":"Feng","year":"2025","journal-title":"Biofactors"},{"issue":"8","key":"10.1016\/j.intimp.2025.115322_bb0840","article-title":"Chimeric antigen receptor costimulation domains modulate human regulatory T cell function [J]. JCI","volume":"5","author":"Boroughs","year":"2019","journal-title":"Insight"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0845","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives [J]","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115322_bb0850","doi-asserted-by":"crossref","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity [J]","volume":"15","author":"Kong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115322_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102986","article-title":"Engineered Treg cells: The heir to the throne of immunotherapy [J]","volume":"144","author":"Stucchi","year":"2024","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.intimp.2025.115322_bb0860","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy [J]","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb0865","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114282119","article-title":"CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory [J]","volume":"119","author":"Kidani","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.intimp.2025.115322_bb0870","first-page":"6512","article-title":"Association between PD-1\/PD-L1 and T regulate cells in early recurrent miscarriage [J]","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.intimp.2025.115322_bb0875","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2019.01.006","article-title":"Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis [J]","volume":"64","author":"Kumar","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.intimp.2025.115322_bb0880","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints [J]","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0885","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function [J]","volume":"202","author":"Chellappa","year":"2019","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0890","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamaoncol.2023.5269","article-title":"Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review [J]","volume":"10","author":"Ghoreifi","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.intimp.2025.115322_bb0895","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001749","article-title":"Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy [J]","volume":"9","author":"van Damme","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0900","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J]","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0905","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J]","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.intimp.2025.115322_bb0910","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma [J]","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.115322_bb0915","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity [J]","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0920","article-title":"Targeting the Adenosine A2A Receptor as a Novel Therapeutic Approach for Renal Cell Carcinoma","volume":"16","author":"Chen","year":"2024","journal-title":"Mechanisms and Clinical Trial Review [J]. Pharmaceutics"},{"issue":"14","key":"10.1016\/j.intimp.2025.115322_bb0925","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma [J]","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0930","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J]","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.intimp.2025.115322_bb0935","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma [J]","volume":"388","author":"Choueiri","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0940","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy [J]","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.intimp.2025.115322_bb0945","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.7150\/thno.96944","article-title":"Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma [J]","volume":"14","author":"Kleinendorst","year":"2024","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0950","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41588-025-02077-6","article-title":"Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma [J]","volume":"57","author":"Liang","year":"2025","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.intimp.2025.115322_bb0955","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer [J]","volume":"29","author":"Halford","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104536","article-title":"A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer [J]","volume":"10","author":"Gouda","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0965","doi-asserted-by":"crossref","first-page":"1862948","DOI":"10.1080\/2162402X.2020.1862948","article-title":"Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma [J]","volume":"10","author":"Kato","year":"2021","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.intimp.2025.115322_bb0970","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial [J]","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104073","article-title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial [J]","volume":"9","author":"Choueiri","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb0980","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40425-019-0567-3","article-title":"Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry [J]","volume":"7","author":"Fishman","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.intimp.2025.115322_bb0985","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.23.02082","article-title":"Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09) [J]","volume":"42","author":"Tannir","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb0990","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2008-01-135319","article-title":"Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines [J]","volume":"112","author":"Morse","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb0995","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10637-020-01058-2","article-title":"A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy [J]","volume":"39","author":"Choueiri","year":"2021","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.intimp.2025.115322_bb1000","article-title":"Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells [J]","author":"Chen","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115322_bb1005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00280-024-04650-y","article-title":"Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors [J]","volume":"94","author":"Shemesh","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb1010","doi-asserted-by":"crossref","first-page":"12513","DOI":"10.1021\/acs.jmedchem.5c00121","article-title":"Discovery of a Selective, Novel TGF-\u03b2R1 Inhibitor GFH018 for the Treatment of Solid Tumors [J]","volume":"68","author":"Jiang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.intimp.2025.115322_bb1015","doi-asserted-by":"crossref","first-page":"13100","DOI":"10.1002\/cam4.5990","article-title":"A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma [J]","volume":"12","author":"Ness","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.intimp.2025.115322_bb1020","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance [J]","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115322_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114624","article-title":"Exploiting regulatory T cells (Tregs): Cutting-edge therapy for autoimmune diseases [J]","volume":"155","author":"Hassan","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"8066","key":"10.1016\/j.intimp.2025.115322_bb1030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41586-025-08795-5","article-title":"Genome-wide CRISPR screen in human T cells reveals regulators of FOXP3 [J]","volume":"642","author":"Chen","year":"2025","journal-title":"Nature"},{"issue":"7812","key":"10.1016\/j.intimp.2025.115322_bb1035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-020-2246-4","article-title":"CRISPR screen in regulatory T cells reveals modulators of Foxp3 [J]","volume":"582","author":"Cortez","year":"2020","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.intimp.2025.115322_bb1040","article-title":"Targeting Alpha-Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD-1 Blockade Immunotherapy in Renal Cell Carcinoma [J]","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"issue":"23","key":"10.1016\/j.intimp.2025.115322_bb1045","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer [J]","volume":"392","author":"Srinivasan","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb1050","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1158\/1535-7163.MCT-25-0101","article-title":"PF-08046032: A Novel, Investigational CD25-Directed Antibody-Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors [J]","volume":"24","author":"Abdelhamed","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.115322_bb1055","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-016-0434-9","article-title":"A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC) [J]","volume":"11","author":"Hainsworth","year":"2016","journal-title":"Target. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb1060","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2767-9764.CRC-24-0082","article-title":"First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPAR\u03b1, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors [J]","volume":"4","author":"Yarchoan","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"15","key":"10.1016\/j.intimp.2025.115322_bb1065","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial [J]","volume":"28","author":"Lee","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2025.115322_bb1070","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial [J]","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.intimp.2025.115322_bb1075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma [J]","volume":"9","author":"Morris","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb1080","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ijc.35288","article-title":"Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial [J]","volume":"156","author":"Gr\u00fcnwald","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2025.115322_bb1085","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma [J]","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.intimp.2025.115322_bb1090","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jjco\/hyae182","article-title":"First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia [J]","volume":"55","author":"Chung","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2025.115322_bb1095","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors [J]","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:46:43Z","timestamp":1772891203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692501313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":219,"alternative-id":["S156757692501313X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115322","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115322"}}